 By John Vandermosten NYSE:CVM READ THE FULL CVM RESEARCH REPORT Second Quarter Fiscal Year 2020 Operational and Financial Results CEL-SCI Corporation NYSE:CVM reported second quarter fiscal year 2020 operational and financial results for the three month period ending March 31, 2020. Following a near nine year duration of the IT-MATTERS trial evaluating Multikine in head and neck cancer, the 